Marco Palmas

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

Paul J. Hesketh, Giada Rizzi, Marco Palmas et al. · Annals of Oncology · 2014 · 223 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of repeated dosing of netupitant, a neurokinin‐1 receptor antagonist, in treating overactive bladder

F. Haab, B. Braticevici, Marco Palmas et al. · Neurourology and Urodynamics · 2013 · 24 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program

Matti Aapro, Paul J. Hesketh, Karin Jordan et al. · The Oncologist · 2016 · 16 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic

Paul J. Hesketh, Marco Palmas, Nicolas Pierre · Supportive Care in Cancer · 2017 · 14 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.

Matti Aapro, Meinolf Karthaus, Lee S. Schwartzberg et al. · Journal of Clinical Oncology · 2014 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +17